This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck & Co., Inc.

Drug Names(s): RemeronSoltab, mirtazapine, Reflex (Japan), Org 3770

Description: The mechanism of action of Remeron (mirtazapine) is unknown. Evidence gathered in preclinical studies suggests that mirtazapine enhances central noradrenergic and serotonergic activity. These studies have shown that mirtazapine acts as an antagonist at central presynaptic a2 adrenergic inhibitory autoreceptors and heteroreceptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors. Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors. Mirtazapine is a also potent antagonist of histamine (H1) receptors, a moderate peripheral a1 adrenergic antagonist, and a moderate antagonist at muscarinic receptors.

Mirtazapine has been classified as a noradrenergic and specific serotonergic antidepressant and referred to as an NaSSA. However, some evidence suggests that in humans it does not have a serotonergic effect.

Deal Structure: Remeron is marketed by Organon, whose parent company is Akzo Nobel.

RemeronSolTab utilizes CIMA LAB's OraSolv fast-dissolve drug delivery system. CIMA is a subsidiary of Cephalon.

Solvay and Organon
In February 2001, Organon announced the co-promotion of RemeronSolTab with Solvay Pharmaceuticals. Through the co-promotion, Solvay Pharmaceuticals' mental health salesrepresentatives co-promotes with Organon's sales representatives. Solvay Pharmaceuticals' medical liaison group will also provide support for the product in the medical community.

Meiji Seika Kaisha
In 2004, Meiji Seika Kaisha obtained rights in mirtazapine in Japan.

Schering-Plough and Organon
In November 2007, Organon was acquired by Schering-Plough.

Merck and Schering-Plough
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine,...See full deal structure in Biomedtracker

Partners: AbbVie Inc. Teva Pharmaceutical Industries Ltd. Meiji Seika Pharma Co., Ltd

Remeron News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug